Empagliflozin with linagliptin for treating type 2 diabetes mellitus in children and adolescents

Empagliflozin and linagliptin are currently in clinical development for type 2 diabetes mellitus (T2DM) in children and adolescents. T2DM is a lifelong condition that develops when the body becomes resistant to, or does not produce enough, insulin – a hormone produced in the pancreas. Insulin is needed for controlling the amount of sugar in the blood. A lack of insulin in T2DM patients causes blood sugar levels to become too high. If blood sugar remains high over a long period of time this can result in serious complications. However, medicinal options for children and adolescents with T2DM are limited at this time.